Pharmaids Pharmaceuticals Ltdte (BSE: 524572) is a Bengaluru, Karnataka-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹106 Cr, it ranks #3,221 by market cap among the 6,137 Indian listed companies on FinBizNet, and #15 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹28.92 (as of 25 Oct 2026), the share price is 46.3% below its 52-week high of ₹53.90 and 13.0% above its 52-week low of ₹25.60. The share price is down 39.0% over one year and down 5.5% over three months.
| Current Price | ₹28.92 |
|---|---|
| Market Cap | ₹106 Cr |
| BSE Code | 524572 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | -9 |
| Return on Equity | -17.82% |
| Return on Assets | -9.39% |
| 52-Week Range | ₹25.60 – ₹53.90 |
| 1-Year Price Change | -39.0% |
| 3-Month Price Change | -5.5% |
| Beta (1Y) | -0.13 |
| Headquarters | Bengaluru, Karnataka |
| Website | www.pharmaids.com |
| Revenue | ₹0 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| EPS (Basic) | ₹0.61 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Pharmaids Pharmaceuticals Limited, together with its subsidiaries, provides contract research and manufacturing services for pharma, biotech, agro, and chemical industries in India. The company offers pharma intermediates, such as Dichloro Benzoyl nitrile, hydrazine carboximidamide 2 methane, pyridine carbonitrile,pyridine carboxylic acid, 8-chloro-10, 11-dihydro-4-aza-5H-dibenzo cycloheptene-5-one, 8-chloro-6,11-dihydro-11 cyclohepta pyridine,2-amino-5-methylthiopene-3-carbonitrile, 5-methyl-2-amino]thiophene-3-carbonitrile, 4-amino-2-methyl-10h-thiene benzodiazepine hydrochloride, 2,4-diamino-6-chloropyrimidine, hydronopol, squalene, 5-chloro-3-phenylanthranil, 2-amino-2,5-dichlorobenzophenone, 6-fluoro-3-4-piperidinyl-1,2-benzisoxazole hcl, 3-2-methyl-4H-pyrido pyrimidin-4-one, 4-n-hexyl resorcinol, triazole kopoxil, CAB-60, CABER-4, CAB-70, DTV, and avobenzone. It also provides active pharmaceuticals ingredients, including voglibose, silodosin, vitamin K2-7, UDCA, P5P, fluralaner,
1. Manufacturing and Selling of Drugs Formulation-This segment produces and markets pharmaceutical formulations in India. It offers allopathic, herbal ayurvedic, and natural drug formulations in various forms, such as tablets, capsules, liquids, powders, etc.
1. Providing Contract Research and Manufacturing Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,73,448 Cr | 71.2 | 16.98% | ₹4,979 Cr | +28.0% |
| Aether Industries Limited | ₹20,419 Cr | 92.1 | 9.81% | ₹327 Cr | +88.8% |
| Alivus Life Sciences Ltd | ₹16,073 Cr | 27.7 | 18.36% | ₹640 Cr | +33.8% |
| Aarti Pharmalabs Ltd | ₹7,922 Cr | 43.2 | 8.49% | ₹536 Cr | -4.1% |
| Solara Active Pharma Sciences Limited | ₹3,361 Cr | -382.6 | -0.63% | ₹417 Cr | +3.3% |
| Sai Parenteral's Limited | ₹2,153 Cr | 110.9 | 2.88% | ₹179 Cr | — |
| KRM Ayurveda Limited | ₹556 Cr | 25.9 | — | ₹32 Cr | — |
| Trident Lifeline Limited | ₹501 Cr | 24.8 | — | — | +39.4% |
| Pharmaids Pharmaceuticals Ltdte | ₹106 Cr | -9 | -17.82% | ₹0 Cr | -39.0% |
Listed by market capitalisation. Ratios are shown for context only.
Pharmaids Pharmaceuticals Ltdte is trading at ₹28.92, with a market capitalisation of ₹106 Cr.
Pharmaids Pharmaceuticals Ltdte operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Pharmaids Pharmaceuticals Ltdte has a P/E of -9 and a return on equity of -17.82%.
Pharmaids Pharmaceuticals Ltdte is listed on the BSE under the scrip code 524572.
Pharmaids Pharmaceuticals Ltdte's share price is down 39.0% over one year and down 5.5% over three months. Its 52-week range is ₹25.60 to ₹53.90.
In Q1 FY27, Pharmaids Pharmaceuticals Ltdte reported revenue of ₹0 Cr and net profit of ₹2 Cr, with basic EPS of ₹0.61 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.